Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Directorate Change

5 Dec 2019 07:00

RNS Number : 7316V
CATCo Reinsurance Opps Fund Ltd
05 December 2019
 

 

 

 

CATCo Reinsurance Opportunities Fund Ltd. (the "Company")

 

Directorate changes

 

 

To: Specialist Fund Segment, London Stock Exchange and Bermuda Stock Exchange

Date: 5 December 2019

 

 

The Board of Directors of the Company are pleased to announce the appointment of Arthur Jones as a non-executive Director of the Company with effect from the conclusion of a Board meeting of the Company held on 4 December 2019. Arthur will also chair the Company's Audit Committee.

 

Arthur is a Chartered Accountant with 35 years' experience in the financial services industry.

 

He is currently Chief Financial Officer of the Consolidated Group of Companies which provides corporate and accounting services to clients in, amongst others, the insurance and investment fund industries. He has been with the Consolidated Group of Companies since 1987. From 2005 to 2018, Arthur served on the Boards of Directors of a number of Bermuda-incorporated hedge and long-only equity funds managed by Martin Currie Group. He is a Bermuda resident.

 

At the date of this announcement, Arthur has no holding in the Ordinary shares or C shares of the Company.

 

There are no matters requiring disclosure pursuant to Listing Rule 9.6.13.

 

Arthur succeeds Alastair Barbour who, as announced on 26 February 2019, had indicated his intention to retire from the Board towards the end of 2019, and who now retires from the Board with immediate effect.

 

James Keyes, Chairman of the Company, commented:

 

"The Board is pleased to confirm Arthur's appointment while expressing our appreciation for Alastair's contribution to the Board and Audit Committee on which he has served over the last eight years. His insight, knowledge and experience have been invaluable. We wish Alastair well for the future."

 

 

For further information:

Markel CATCo Investment Management Ltd.

 

Judith Wynne

General Counsel

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief of Investor Marketing

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

Numis Securities Limited

 

David Benda / Hugh Jonathan

Telephone: +44 (0) 20 7260 1000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUGGGCPUPBGBC
Date   Source Headline
29th Mar 201111:40 amRNSIssue of Equity
29th Mar 201111:36 amRNSDirector/PDMR Shareholding
7th Mar 20111:49 pmRNSNet Asset Value(s)
7th Feb 20118:30 amRNSPortfolio Update
7th Feb 20118:11 amRNSNet Asset Value(s)
14th Jan 20117:00 amRNSPortfolio Update
7th Jan 20113:33 pmRNSHolding(s) in Company
23rd Dec 201011:00 amRNSHolding(s) in Company
20th Dec 20107:00 amRNSResult of Placing and Admission to SFM
13th Jul 20064:12 pmRNSHolding(s) in Company
10th Jul 20063:20 pmRNSHolding(s) in Company
7th Jul 20062:51 pmRNSOffer for Cambridge Antibody
3rd Jul 20064:56 pmRNSDirectorate Change
30th Jun 20064:12 pmRNSHolding(s) in Company
30th Jun 20064:06 pmRNSDelisting
30th Jun 200610:27 amRNSAdditional Listing
30th Jun 20067:02 amRNSOffer for Cambridge Antibody
27th Jun 20062:26 pmRNSHolding(s) in Company
27th Jun 200612:34 pmRNSHolding(s) in Company
23rd Jun 20062:25 pmRNSAppointment of Directors
22nd Jun 20063:07 pmRNSRule 8.3- CAT
22nd Jun 200611:31 amRNSCAT Limited appoints new CE
22nd Jun 200611:11 amRNSEPT Disclosure
22nd Jun 200611:09 amRNSEPT Disclosure
22nd Jun 20067:02 amRNSOffer for Cambridge Antibody
21st Jun 20065:11 pmRNSRule 8.1- C.A.T.
21st Jun 200611:30 amRNSEPT Disclosure
21st Jun 200610:20 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
19th Jun 20063:25 pmRNSRule 8.3 - Cambridge Antibody
19th Jun 20061:07 pmRNSRule 8.3- (CAT)
19th Jun 200611:30 amRNSEPT Disclosure
19th Jun 200611:23 amRNSEPT Disclosure
19th Jun 200610:33 amRNSEPT Disclosure
16th Jun 200611:45 amRNSEPT Disclosure
16th Jun 200611:24 amRNSEPT Disclosure
16th Jun 200611:08 amRNSEPT Disclosure
15th Jun 20065:01 pmRNSEPT Disclosure
15th Jun 20062:48 pmRNSRule 8.3- (CAT)
15th Jun 20062:17 pmRNSRule 2.10 Announcement
15th Jun 200612:45 pmRNSEPT Disclosure
15th Jun 200611:36 amRNSEPT Disclosure
14th Jun 20063:38 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20063:05 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20061:43 pmRNSRule 8.3- (CAT)
14th Jun 200611:36 amRNSEPT Disclosure
14th Jun 200611:15 amRNSEPT Disclosure
14th Jun 200610:59 amRNSEPT Disclosure
14th Jun 200610:23 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.